CD8A and neoplasm: Mn2+ promotes the maturation of dendritic cells and macrophages, enhances the presentation of tumor‐specific antigens, stimulates the activation of CD8+ T cells and NK cells, as well as the secretion of type I interferon, making it a potential adjuvant candidate.[27, 28, 29] Nevertheless, the restricted immune activation and limited accumulation of free Mn2+ in secondary lymphoid organs, coupled with potential neurotoxicity, hinder its widespread application in cancer immunotherapy.[30, 31]